Supplementary Figure 6 from MALAT1 is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance Through EZH2

Supplementary Figure 6. ROC analysis was performed to establish the potential cut-off values of MALAT1 (A) and miR-218 (B) in 46 primary CRC tissues for distinguishing responding and non-responding patients who had received standard FOLFOX treatment.